Decision: Favourable

Decisions Table

Study Title:

Single arm phase 2 trial of neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a standard chemotherapy-sparing approach to curative-intent treatment – SHAMROCK study

  • NREC Code:

    22-NREC-CT-173

  • Decision:

    Favourable

  • Meeting Date:

    23/11/2022

  • Study Type:

    CT application

  • Principal Investigator:

    Prof Bryan Hennessy

  • PI Institution:

    St. James's Hospital, Dublin

  • Sponsor:

    Beaumont Hospital

Scroll to Top